+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Targeted Therapy), End Use (Hospitals, Specialty Clinics), and Region with Growth Forecasts, 2025-2030- Product Image
Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Targeted Therapy), End Use (Hospitals, Specialty Clinics), and Region with Growth Forecasts, 2025-2030- Product Image
New

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Targeted Therapy), End Use (Hospitals, Specialty Clinics), and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5998930
Description Jump to:
The Metastatic Lung Adenocarcinoma Treatment Market was valued at USD 4.90 billion in 2024, and is projected to reach USD 9.29 billion by 2030, rising at a CAGR of 11.30%. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights

  • Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2024, the chemotherapy segment accounted for the largest revenue share of 36% in metastatic lung adenocarcinoma treatment market
  • The hospital segment accounts for the largest revenue share of 63.9% in 2024. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
  • The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors
  • The targeted therapy segment is anticipated to emerge as the fastest-growing segment and register a CAGR of 12.9% from 2025 to 2030, owing to its ability to target specific molecular drivers of cancer precisely.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatment Business Analysis
4.1. Treatment Market Share, 2024 & 2030
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
4.4. Chemotherapy
4.4.1. Chemotherapy Market, 2018-2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted Therapy Market, 2018-2030 (USD Million)
4.6. Immunotherapy
4.6.1. Immunotherapy Market, 2018-2030 (USD Million)
4.7. Radiation Therapy
4.7.1. Radiation Therapy Market, 2018-2030 (USD Million)
4.8. Other
4.8.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Business Analysis
5.1. End Use Market Share, 2024 & 2030
5.2. End Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Hospitals
5.4.1. Hospitals Market, 2018-2030 (USD Million)
5.5. Specialty Clinics
5.5.1. Specialty Clinics Market, 2018-2030 (USD Million)
5.6. Other
5.6.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamic
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamic
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamic
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamic
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamic
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamic
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Spain
6.5.5.1. Key Country Dynamic
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Spain Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Italy
6.5.6.1. Key Country Dynamic
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Italy Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamic
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Denmark Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamic
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Norway Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamic
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamic
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamic
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamic
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamic
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamic
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamic
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamic
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamic
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamic
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamic
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamic
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamic
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Pfizer Inc.
7.5.1.1. Participant’s Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Eli Lilly and Company
7.5.2.1. Participant’s Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. AstraZeneca
7.5.3.1. Participant’s Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Bristol-Myers Squibb Company
7.5.4.1. Participant’s overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Boehringer Ingelheim International GmbH
7.5.5.1. Participant’s Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Novartis AG
7.5.6.1. Participant’s Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Merck KGaA (EMD Serono)
7.5.7.1. Participant’s Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. F. Hoffmann-La Roche Ltd
7.5.8.1. Participant’s Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. GSK plc.
7.5.9.1. Participant’s Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. AbbVie Inc.
7.5.10.1. Participant’s Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Metastatic Lung Adenocarcinoma Treatment Market, by Region, 2018-2030 (USD Million)
Table 4. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 5. Global Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 6. North America Metastatic Lung Adenocarcinoma Treatment Market, by Country, 2018-2030 (USD Million)
Table 7. North America Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 8. North America Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 9. U.S. Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 10. U.S. Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 11. Canada Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 12. Canada Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 13. Mexico Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 14. Mexico Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 15. Europe Metastatic Lung Adenocarcinoma Treatment Market, by Country, 2018-2030 (USD Million)
Table 16. Europe Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 17. Europe Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 18. UK Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 19. UK Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 20. Germany Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 21. Germany Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 22. France Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 23. France Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 24. Spain Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 25. Spain Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 26. Italy Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 27. Italy Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 28. Denmark Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 29. Denmark Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 30. Sweden Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 31. Sweden Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 32. Norway Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 33. Norway Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 34. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, by Country, 2018-2030 (USD Million)
Table 35. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 36. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 37. China Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 38. China Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 39. Japan Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 40. Japan Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 41. India Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 42. India Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 43. South Korea Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 44. South Korea Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 45. Australia Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 46. Australia Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 47. Thailand Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 48. Thailand Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 49. Latin America Metastatic Lung Adenocarcinoma Treatment Market, by Country, 2018-2030 (USD Million)
Table 50. Latin America Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 51. Latin America Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 52. Brazil Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 53. Brazil Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 54. Argentina Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 55. Argentina Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 56. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, by Country, 2018-2030 (USD Million)
Table 57. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 58. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 59. South Africa Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 60. South Africa Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 61. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 62. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 63. UAE Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 64. UAE Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
Table 65. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 66. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, by End Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Metastatic Lung Adenocarcinoma Treatment Market Segmentation
Figure 2 Market Research Process
Figure 3 Data Triangulation Techniques
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Value-Chain-Based Sizing & Forecasting
Figure 7 Market Formulation & Validation
Figure 8 Market Snapshot
Figure 9 Treatment and End Use Outlook (USD Million)
Figure 10 Competitive Landscape
Figure 11 Metastatic Lung Adenocarcinoma Treatment Market Dynamics
Figure 12 Metastatic Lung Adenocarcinoma Treatment Market: Porter’s Five Forces Analysis
Figure 13 Metastatic Lung Adenocarcinoma Treatment Market: PESTLE Analysis
Figure 14 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Segment Dashboard
Figure 15 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Market Share Analysis, 2024 & 2030
Figure 16 Chemotherapy Market, 2018-2030 (USD Million)
Figure 17 Targeted Therapy Market, 2018-2030 (USD Million)
Figure 18 Immunotherapy Market, 2018-2030 (USD Million)
Figure 19 Radiation Therapy Market, 2018-2030 (USD Million)
Figure 20 Others Market, 2018-2030 (USD Million)
Figure 21 Metastatic Lung Adenocarcinoma Treatment Market: End Use Segment Dashboard
Figure 22 Metastatic Lung Adenocarcinoma Treatment Market: End Use Market Share Analysis, 2024 & 2030
Figure 23 Hospitals Market, 2018-2030 (USD Million)
Figure 24 Specialty Clinics Market, 2018-2030 (USD Million)
Figure 25 Others Market, 2018-2030 (USD Million)
Figure 26 Metastatic Lung Adenocarcinoma Treatment Market Revenue, by Region
Figure 27 Regional Marketplace: Key Takeaways
Figure 28 Regional Marketplace: Key Takeaways
Figure 29 North America Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 30 U.S. Country Dynamics
Figure 31 U.S. Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 32 Canada Country Dynamics
Figure 33 Canada Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 34 Mexico Country Dynamics
Figure 35 Mexico Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 36 Europe Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 37 UK Country Dynamics
Figure 38 UK Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 39 Germany Country Dynamics
Figure 40 Germany Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 41 France Country Dynamics
Figure 42 France Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 43 Spain Country Dynamics
Figure 44 Spain Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 45 Italy Country Dynamics
Figure 46 Italy Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 47 Denmark Country Dynamics
Figure 48 Denmark Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 49 Sweden Country Dynamics
Figure 50 Sweden Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 51 Norway Country Dynamics
Figure 52 Norway Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 53 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 54 Japan Country Dynamics
Figure 55 Japan Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 56 China Country Dynamics
Figure 57 China Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 58 India Country Dynamics
Figure 59 India Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 60 South Korea Country Dynamics
Figure 61 South Korea Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 62 Australia Country Dynamics
Figure 63 Australia Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 64 Thailand Country Dynamics
Figure 65 Thailand Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 66 Latin America Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 67 Brazil Country Dynamics
Figure 68 Brazil Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 69 Argentina Country Dynamics
Figure 70 Argentina Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 71 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 72 South Africa Country Dynamics
Figure 73 South Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 74 Saudi Arabia Country Dynamics
Figure 75 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 76 UAE Country Dynamics
Figure 77 UAE Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 78 Kuwait Key Country Dynamics
Figure 79 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, 2018-2030 (USD Million)
Figure 80 Company Categorization
Figure 81 Company Market Position Analysis
Figure 82 Strategic Framework

Companies Mentioned

The major companies profiled in this Metastatic Lung Adenocarcinoma Treatment market report include:
  • Pfizer Inc.
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Merck KGaA (EMD Serono)
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • AbbVie Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.29 Billion
Compound Annual Growth Rate11.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), End-Use (Hospitals, Specialty Clinics), and Region (North America, Europe) with Growth Forecasts, 2025-2030 - Product Image

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), End-Use (Hospitals, Specialty Clinics), and Region (North America, Europe) with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Lung Adenocarcinoma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Lung Adenocarcinoma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Lung Adenocarcinoma Market Report and Forecast 2024-2032 - Product Image

Lung Adenocarcinoma Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Non-Small Cell Lung Cancer - Market Insight, Epidemiology, and Market Forecast -2034 - Product Image

Non-Small Cell Lung Cancer - Market Insight, Epidemiology, and Market Forecast -2034

  • Report
  • 880 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.